Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Cardiff Oncology Inc

Cardiff Oncology Shares Slide Over 26% In Premarket Trading After Mixed Q2

Following a disappointing second-quarter earnings report, Cardiff Oncology Inc. (NASDAQ:CRDF) experienced a 26.28% drop in its stock value during pre-market trading on Wednesday after reporting mixed Q2 earnings.

Benzinga · Jul 30, 2025

Hoth Therapeutics And 3 Other Stocks Under $3 Insiders Are Aggressively Buying

The Dow Jones jumped by around 197 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment…

Benzinga · Sep 20, 2022

3 Falling Stock to Think About Selling Short Right Now

Worries about sky-high inflation, the Federal Reserve’s hawkish stance, and recession prospects have spurred market sell-off lately. Moreover, investors expect increased market volatility as analysts cut down their earnings estimates. Given the uncertain market conditions, fundamentally weak and losing stocks Snap (SNAP), Allegiant Travel (ALGT), and Cardiff Oncology (CRDF) could…

StockNews.com · Sep 7, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

5 Oncology Stocks Wall Street Predicts Will Rally 135% or More

The oncology industry is expected to grow considerably in 2022, driven by the rising occurrence of cancer in the U.S. population. Furthermore, increasing investments by biopharmaceutical companies and the government should fuel the industry's growth. Given the industry's bright growth prospects, Wall Street analysts expect the stocks of quality oncology…

StockNews.com · May 31, 2022

Why Cardiff Oncology Shares Are Falling

Cardiff Oncology Inc (NASDAQ: CRDF) shares are trading lower after the company announced data from its lead clinical program evaluating onvansertib in combination with standard-of-care FOLFIRI/bevacizumab.

Benzinga · Jan 19, 2022

Cardiff Oncology Slumps On New Data From Lead Program In Metastatic Colorectal Cancer

Cardiff Oncology Inc (NASDAQ: CRDF) posted

Benzinga · Jan 19, 2022

Coverage From

People

Mangeet Kaur BounsMangeet

595 stories

Evan Spiegel

94 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.